

Stefano Luzzago

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6880288/publications.pdf>

Version: 2024-02-01

115
papers

1,258
citations

471509

17
h-index

526287

27
g-index

118
all docs

118
docs citations

118
times ranked

1707
citing authors

#	ARTICLE	IF	CITATIONS
1	A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma. <i>BJU International</i> , 2022, 129, 182-193.	2.5	16
2	Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies. <i>Urologia Internationalis</i> , 2022, 106, 75-82.	1.3	4
3	Repeat MRI during active surveillance: natural history of prostatic lesions and upgrading rates. <i>BJU International</i> , 2022, 129, 524-533.	2.5	4
4	Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	2.5	8
5	A comprehensive evaluation of sexual and reproductive outcomes following robot-assisted retroperitoneal lymph node dissection for nonseminomatous germ cell tumor. <i>Asian Journal of Andrology</i> , 2022, 24, 579.	1.6	6
6	The Clinical Role of SRSF1 Expression in Cancer: A Review of the Current Literature. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 2268.	2.5	4
7	Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guérin Immunotherapy. <i>Diagnostics</i> , 2022, 12, 586.	2.6	14
8	Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer. <i>World Journal of Urology</i> , 2022, , 1.	2.2	0
9	Radiomics in prostate cancer: an up-to-date review. <i>Therapeutic Advances in Urology</i> , 2022, 14, 175628722211090.	2.0	62
10	Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis. <i>World Journal of Urology</i> , 2021, 39, 461-472.	2.2	15
11	Radical cystectomy improves survival in patients with stage T1 squamous cell carcinoma and neuroendocrine carcinoma of the urinary bladder. <i>European Journal of Surgical Oncology</i> , 2021, 47, 463-469.	1.0	7
12	Radical cystectomy plus chemotherapy in patients with pure squamous cell bladder carcinoma: a population-based study. <i>World Journal of Urology</i> , 2021, 39, 813-822.	2.2	6
13	PSA, stage, grade and prostate cancer specific mortality in Asian American patients relative to Caucasians according to the United States Census Bureau race definitions. <i>World Journal of Urology</i> , 2021, 39, 787-796.	2.2	10
14	Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 265-273.	4.2	44
15	MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 406-413.	3.9	9
16	The effect of sex on disease stage and survival after radical cystectomy: a population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 236.e1-236.e7.	1.6	10
17	Adjuvant radiotherapy in node positive prostate cancer patients: a debate still on. when, for whom?. <i>BJU International</i> , 2021, 127, 454-462.	2.5	3
18	Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 235.e5-235.e14.	1.6	8

#	ARTICLE	IF	CITATIONS
19	Prognostic factors in patients with small renal masses: a comparison between <2 vs. 2.1-4cm renal cell carcinomas. <i>Cancer Causes and Control</i> , 2021, 32, 119-126.	1.8	1
20	Contemporary rates and predictors of open conversion during minimally invasive partial nephrectomy for kidney cancer. <i>Surgical Oncology</i> , 2021, 36, 131-137.	1.6	4
21	Robot-Assisted Radical Cystectomy for Nonmetastatic Urothelial Carcinoma of Urinary Bladder: A Comparison Between Intracorporeal Versus Extracorporeal Orthotopic Ileal Neobladder. <i>Journal of Endourology</i> , 2021, 35, 151-158.	2.1	13
22	MRI-based radiomics signature for localized prostate cancer: a new clinical tool for cancer aggressiveness prediction? Sub-study of prospective phase II trial on ultra-hypofractionated radiotherapy (AIRC IG-13218). <i>European Radiology</i> , 2021, 31, 716-728.	4.5	31
23	OUP accepted manuscript. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1149-1157.	1.3	4
24	Impact of Perioperative Immunonutrition on Complications in Patients Undergoing Radical Cystectomy: A Retrospective Analysis. <i>Integrative Cancer Therapies</i> , 2021, 20, 153473542110194.	2.0	5
25	Prognostic role of the systemic immune-inflammatory index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2641-2650.	4.2	21
26	Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2021, 10, 609-619.	1.4	5
27	Assessment of PSIM (Prostatic Systemic Inflammatory Markers) Score in Predicting Pathologic Features at Robotic Radical Prostatectomy in Patients with Low-Risk Prostate Cancer Who Met the Inclusion Criteria for Active Surveillance. <i>Diagnostics</i> , 2021, 11, 355.	2.6	12
28	Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?. <i>Clinical and Translational Oncology</i> , 2021, 23, 1717-1726.	2.4	15
29	Apparent Diffusion Coefficient and Other Preoperative Magnetic Resonance Imaging Features for the Prediction of Positive Surgical Margins in Prostate Cancer Patients Undergoing Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e335-e345.	1.9	7
30	Comparison between small renal masses 0-2 cm vs. 2.1-4 cm in size: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 239.e1-239.e7.	1.6	5
31	Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non-clear Cell Renal Cell Carcinoma Patients. <i>European Urology Focus</i> , 2021, 7, 598-607.	3.1	10
32	Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-analysis of Prospective Studies. <i>European Urology Open Science</i> , 2021, 27, 19-28.	0.4	11
33	Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 651745.	2.8	11
34	Contemporary Age-adjusted Incidence and Mortality Rates of Renal Cell Carcinoma: Analysis According to Gender, Race, Stage, Grade, and Histology. <i>European Urology Focus</i> , 2021, 7, 644-652.	3.1	28
35	Metabolic syndrome predicts worse perioperative outcomes in patients treated with radical prostatectomy for non-metastatic prostate cancer. <i>Surgical Oncology</i> , 2021, 37, 101519.	1.6	2
36	Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review. <i>Cancers</i> , 2021, 13, 3278.	3.7	6

#	ARTICLE	IF	CITATIONS
37	Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1729-1735.	2.2	3
38	A novel nomogram predicting lymph node invasion among patients with prostate cancer: The importance of extracapsular extension at multiparametric magnetic resonance imaging. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 431.e15-431.e22.	1.6	11
39	Robot-Assisted Intracorporeal Orthotopic Ileal Neobladder: Description of the "Shell" Technique. <i>Journal of Clinical Medicine</i> , 2021, 10, 3601.	2.4	4
40	Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches. <i>Frontiers in Oncology</i> , 2021, 11, 732766.	2.8	2
41	The emerging landscape of tumor marker panels for the identification of aggressive prostate cancer: the perspective through bibliometric analysis of an Italian translational working group in uro-oncology. <i>Minerva Urology and Nephrology</i> , 2021, 73, 442-451.	2.5	23
42	Uro-oncologic patient management during the COVID-19 pandemic: survey findings from an Italian oncologic hub. <i>Future Oncology</i> , 2021, 17, 3615-3625.	2.4	0
43	Penile-sparing surgery for patients with superficial or initially invasive squamous cell carcinoma of the penis: long-term oncological outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 736.e1-736.e7.	1.6	2
44	Comparison of Mexican-American vs Caucasian prostate cancer active surveillance candidates. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 74.e1-74.e7.	1.6	4
45	Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies. <i>World Journal of Urology</i> , 2021, , 1.	2.2	3
46	Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicentre study. <i>Minerva Urology and Nephrology</i> , 2021, , .	2.5	3
47	Impact of the preoperative modified glasgow prognostic score on disease outcome after radical cystectomy for urothelial carcinoma of the bladder. <i>Minerva Urology and Nephrology</i> , 2021, , .	2.5	8
48	Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 129-137.e3.	1.9	11
49	Confirmatory multiparametric magnetic resonance imaging at recruitment confers prolonged stay in active surveillance and decreases the rate of upgrading at follow-up. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 94-101.	3.9	4
50	Prostate cancer characteristics and cancer-specific mortality of Native American patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 277-285.	3.9	6
51	Patient frailty predicts worse perioperative outcomes and higher cost after radical cystectomy. <i>Surgical Oncology</i> , 2020, 32, 8-13.	1.6	39
52	Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 35-44.e1.	1.9	2
53	Survival of Contemporary Patients With Non-metastatic Small-cell Carcinoma of Urinary Bladder, According to Alternative Treatment Modalities. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e450-e456.	1.9	5
54	Unmarried men have worse oncologic outcomes after radical cystectomy for nonmetastatic urothelial bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 76.e1-76.e9.	1.6	22

#	ARTICLE	IF	CITATIONS
55	Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 117-128.e5.	1.9	6
56	Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 936.e7-936.e14.	1.6	3
57	Bladder cancer incidence rates and trends in young adults aged 20-39 years. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 934.e11-934.e19.	1.6	5
58	Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 929.e11-929.e19.	1.6	8
59	The Effect of Systemic Chemotherapy on Survival in Patients With Localized, Regional, or Metastatic Adenocarcinoma of the Urinary Bladder. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 567-574.	1.3	3
60	Clinical evaluation and disease management of PI-RADS 3 lesions. Analysis from a single tertiary high-volume center. <i>Scandinavian Journal of Urology</i> , 2020, 54, 382-386.	1.0	2
61	Assessment of other-cause mortality in localized renal cell carcinoma patients within 15 years: A population-based analysis. <i>Journal of Surgical Oncology</i> , 2020, 122, 1506-1513.	1.7	1
62	Long-Term Follow-Up Outcomes after Percutaneous US/CT-Guided Radiofrequency Ablation for cT1a-b Renal Masses: Experience from Single High-Volume Referral Center. <i>Cancers</i> , 2020, 12, 1183.	3.7	15
63	Robot-assisted inguinal lymphadenectomy: preliminary experience and perioperative outcomes from an Italian referral center. <i>Therapeutic Advances in Urology</i> , 2020, 12, 175628722091338.	2.0	3
64	A Guide for Oncologic Patient Management during Covid-19 Pandemic: The Initial Experience of an Italian Oncologic Hub with Exemplificative Focus on Uro-Oncologic Patients. <i>Cancers</i> , 2020, 12, 1513.	3.7	11
65	Minimally invasive versus open radical cystectomy: long term oncologic outcomes compared. <i>Translational Andrology and Urology</i> , 2020, 9, 1006-1008.	1.4	2
66	A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings. <i>BJU International</i> , 2020, 126, 104-113.	2.5	21
67	Metabolic Syndrome Predicts Worse Perioperative Outcomes in Patients Treated With Partial Nephrectomy for Renal Cell Carcinoma. <i>Urology</i> , 2020, 140, 91-97.	1.0	2
68	Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non-clear cell histology: A contemporary population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 506-514.	1.6	4
69	Contemporary Rates and Predictors of Open Conversion During Minimally Invasive Radical Prostatectomy for Nonmetastatic Prostate Cancer. <i>Journal of Endourology</i> , 2020, 34, 600-607.	2.1	6
70	Renal cell carcinoma incidence rates and trends in young adults aged 20-39 years. <i>Cancer Epidemiology</i> , 2020, 67, 101762.	1.9	14
71	Contemporary conditional cancer-specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract. <i>Journal of Surgical Oncology</i> , 2020, 121, 1154-1161.	1.7	20
72	The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages. <i>Cancer Causes and Control</i> , 2020, 31, 283-290.	1.8	9

#	ARTICLE	IF	CITATIONS
73	Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 537-544.	1.6	13
74	Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities. <i>Cancer Causes and Control</i> , 2020, 31, 263-272.	1.8	9
75	Rates of other-cause mortality after radical cystectomy are decreasing over time—A population-based analysis over two decades. <i>Journal of Surgical Oncology</i> , 2020, 121, 1329-1336.	1.7	5
76	Differences in short-term outcomes between open versus robot-assisted radical cystectomy in frail malnourished patients. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1347-1352.	1.0	8
77	Histologic Subtype, Tumor Grade, Tumor Size, and Race Can Accurately Predict the Probability of Synchronous Metastases in T2 Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e610-e618.	1.9	10
78	Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder. <i>World Journal of Urology</i> , 2020, 38, 2819-2826.	2.2	10
79	Prostate Cancer Grade and Stage Misclassification in Active Surveillance Candidates: Black Versus White Patients. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1492-1499.	4.9	8
80	Effect of Age on Cancer-specific Mortality in Patients With Urothelial Carcinoma of the Urinary Bladder. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 880-888.	1.3	5
81	Small Renal Masses With Tumor Size 0 to 2 cm: A SEER-Based Study and Validation of NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1340-1347.	4.9	6
82	A 25-year Period Analysis of Other-cause Mortality in Localized Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 395-401.	1.9	9
83	The effect of radical cystectomy on survival in patients with metastatic urothelial carcinoma of the urinary bladder. <i>Journal of Surgical Oncology</i> , 2019, 120, 1266-1275.	1.7	6
84	Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e602-e611.	1.9	17
85	Medical Expulsive Therapy for Symptomatic Distal Ureter Stones: Is the Combination of Bromelain and Tamsulosin More Effective than Tamsulosin Alone? Preliminary Results of a Single-Center Study. <i>Urologia Internationalis</i> , 2019, 102, 145-152.	1.3	5
86	Multiparametric Magnetic Resonance Imaging Second Opinion May Reduce the Number of Unnecessary Prostate Biopsies: Time to Improve Radiologists' Training Program?. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 88-96.	1.9	22
87	Neutrophil, Platelets, and Eosinophil to Lymphocyte Ratios Predict Gleason Score Upgrading in Low-Risk Prostate Cancer Patients. <i>Urologia Internationalis</i> , 2019, 102, 43-50.	1.3	43
88	Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract. <i>World Journal of Urology</i> , 2019, 37, 1329-1337.	2.2	4
89	Robot-assisted Partial Nephrectomy: 5-yr Oncological Outcomes at a Single European Tertiary Cancer Center. <i>European Urology Focus</i> , 2019, 5, 636-641.	3.1	19
90	Long-term oncologic and functional outcomes after robot-assisted partial nephrectomy in elderly patients. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 31-37.	3.9	26

#	ARTICLE	IF	CITATIONS
91	Thulium Laser Treatment of Upper Urinary Tract Carcinoma: A Multi-Institutional Analysis of Surgical and Oncological Outcomes. <i>Journal of Endourology</i> , 2018, 32, 257-263.	2.1	51
92	Thulium-“yttrium”-aluminum-“garnet (Tm:YAG) laser treatment of penile cancer: oncological results, functional outcomes, and quality of life. <i>World Journal of Urology</i> , 2018, 36, 265-270.	2.2	15
93	Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study. <i>European Urology Oncology</i> , 2018, 1, 268-275.	5.4	5
94	Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol. <i>Urologia Internationalis</i> , 2018, 101, 56-64.	1.3	17
95	In-hospital length of stay after major surgical oncological procedures. <i>European Journal of Surgical Oncology</i> , 2018, 44, 969-974.	1.0	34
96	MP77-20 MULTIPARAMETRIC MRI REPRESENTS AN ADDED VALUE BUT NOT A SUBSTITUTE OF FOLLOW-UP BIOPSIES IN PATIENTS ON ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER. <i>Journal of Urology</i> , 2017, 197, .	0.4	0
97	MP77-16 FIRST REPEATED BIOPSY REPRESENTS THE MOST INFORMATIVE PREDICTOR OF PROGRESSION-FREE SURVIVAL AT 3 YEARS FOLLOW-UP IN PATIENTS INCLUDED IN AN ACTIVE SURVEILLANCE PROTOCOL FOR LOW-RISK PROSTATE CANCER. <i>Journal of Urology</i> , 2017, 197, .	0.4	1
98	MP58-09 PREDICTING LOCAL FAILURE AFTER RADICAL CYSTECTOMY IN BLADDER CANCER PATIENTS: IMPLICATIONS FOR THE SELECTION OF CANDIDATES AT ADJUVANT RADIATION THERAPY. <i>Journal of Urology</i> , 2017, 197, .	0.4	0
99	PD51-11 PATHOLOGICAL FINDINGS AT RADICAL PROSTATECTOMY AFTER INITIAL ACTIVE SURVEILLANCE IN LOW-RISK PROSTATE CANCER PATIENTS. DID WE MISS THE CHANCE TO CURE?. <i>Journal of Urology</i> , 2017, 197, .	0.4	0
100	Effect of Stage Migration on Bladder Cancer: A Slow but Steady Improvement in Long-Term Survival Rates After Radical Cystectomy in Previous 25 Years. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e223-e228.	1.9	5
101	Incidence and Predictors of 30-Day Readmission After Robot-Assisted Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 67-71.	1.9	14
102	The surgical management of patients with clinical stage T4 bladder cancer: A single institution experience. <i>European Journal of Surgical Oncology</i> , 2017, 43, 808-814.	1.0	8
103	PD33-02 VARIANT HISTOLOGIC DIFFERENTIATION IN BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY: INCIDENCE AND LONG TERM SURVIVAL IN A SINGLE INSTITUTION STUDY.. <i>Journal of Urology</i> , 2016, 195, .	0.4	0
104	MP63-11 PREOPERATIVE PLATELET TO LYMPHOCYTE RATIO AS A PREDICTOR OF SURVIVAL AFTER RADICAL CYSTECTOMY DUE TO BLADDER CANCER. <i>Journal of Urology</i> , 2016, 195, .	0.4	0
105	PD33-10 THE PRESENCE OF RESIDUAL CARCINOMA IN SITU ALONE (PTIS) IN PATIENTS TREATED WITH RADICAL CYSTECTOMY DOES NOT AFFECT LONG TERM RECURRENCE AND SURVIVAL RATES. <i>Journal of Urology</i> , 2016, 195, .	0.4	0
106	MP14-06 THE IMPACT OF ADJUVANT RADIOTHERAPY ON CANCER-SPECIFIC MORTALITY IN PROSTATE CANCER PATIENTS WITH SEMINAL VESICLE INVOLVEMENT: A COMPETING-RISKS REGRESSION ANALYSIS. <i>Journal of Urology</i> , 2016, 195, .	0.4	0
107	Determinants of long-term survival of patients with locally advanced prostate cancer: the role of extensive pelvic lymph node dissection. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 63-67.	3.9	41
108	Preoperative Favorable Characteristics in Bladder Cancer Patients Cannot Substitute the Necessity of Extended Lymphadenectomy During Radical Cystectomy: A Sensitivity Curve Analysis. <i>Urology</i> , 2016, 88, 97-103.	1.0	11

#	ARTICLE	IF	CITATIONS
109	The Impact of Perioperative Blood Transfusion on Survival of Bladder Cancer Patients Submitted to Radical Cystectomy: Role of Anemia Status. <i>European Urology Focus</i> , 2016, 2, 86-91.	3.1	20
110	Effect on postoperative survival of the status of distal ureteral margin: The necessity to achieve negative margins at the time of radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 59.e15-59.e22.	1.6	16
111	MP4-16 PATTERNS OF CLINICAL RECURRENCE AND IMPACT OF SITE OF METASTASIS ON MORTALITY OF PATIENTS WITH NODE-POSITIVE PROSTATE CANCER AFTER RADICAL PROSTATECTOMY AND EXTENDED PELVIC LYMPH NODE DISSECTION. <i>Journal of Urology</i> , 2015, 193, .	0.4	0
112	MP72-04 IMPACT OF THE SITE OF RECURRENCE AFTER RADICAL CYSTECTOMY ON SURVIVAL: DIFFERENT SITES FOR DIFFERENT OUTCOMES.. <i>Journal of Urology</i> , 2015, 193, .	0.4	0
113	MP82-03 SALVAGE LYMPH NODE DISSECTION FOR CLINICALLY RECURRENT PROSTATE CANCER: WHICH PATIENTS DO BENEFIT FROM THIS APPROACH?. <i>Journal of Urology</i> , 2015, 193, .	0.4	0
114	Effect of Allogeneic Intraoperative Blood Transfusion on Survival in Patients Treated With Radical Cystectomy for Nonmetastatic Bladder Cancer: Results From a Single High-Volume Institution. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 562-567.	1.9	37
115	Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term Survival. <i>European Urology</i> , 2015, 68, 777-784.	1.9	48